Article

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors

2025-03-02

Abstract excerpt

Tumor cells often cope with elevated levels of replication stress (RS) causing increased dependency on ATR-CHK1 signalling. We previously presented RRM2, the regulatory component of the ribonucleotide reductase (RNR) enzyme, as novel dependency in neuroblastoma, in keeping with its role in RS resistance. We identified strong synergism for combined RRM2-CHK1 inhibition using the iron chelator triapine and prexasert...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 419005a9-5c62-59c8-a723-1a947f04fe1a
DOI: 10.1101/2025.02.26.640375

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitorsDOI 10.1101/2025.02.26.640375Read

RRM2 is a target for synthetic lethal interactions with replication stress checkpoint addiction in high-risk neuroblastomaSemantic proximity Read

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibitionSemantic proximity Read

DNA repair and replicative stress addiction in neuroblastomaSemantic proximity Read

TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stressSemantic proximity Read

MYCN amplification and ATRX mutations are incompatible in neuroblastoma.Semantic proximity Read

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignanciesSemantic proximity Read

High regeneration-associated stress defines a distinct HCC subgroup with therapeutically exploitable vulnerabilitiesSemantic proximity Read

MYCN Amplification and ATRX Mutations are Incompatible in NeuroblastomaSemantic proximity Read

Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and PresentSemantic proximity Read

Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degradersSemantic proximity Read

Ribonucleotide Reductase Subunit Switching in Hepatoblastoma Drug Response and RelapseSemantic proximity Read

Ribonucleotide Reductase Regulatory Subunit M2 as a Driver of Glioblastoma TMZ-Resistance through Modulation of dNTP ProductionSemantic proximity Read